Cowen analyst Eric Schmidt reiterated an Outperform rating on Kite Pharma (NASDAQ: KITE) following an investor luncheon with senior management ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE